

S0040-4039(96)00632-6


## An Expedient Route to the Synthesis of Adenophostin A

Nicole C.R. van Straten, Gijsbert A. van der Marel and Jacques H. van Boom\*

Leiden Institute of Chemistry, Gorlaeus Laboratories, P.O. Box 9502, 2300 RA Leiden, The Netherlands

**Abstract:** Glycosylation of 1,2-*O*-isopropylidene-5-*O*-*tert*-butyldiphenylsilyl- $\alpha$ -D-ribofuranose (**8**) with ethyl 3,4,6-tri-*O*-acetyl-2-*O*-benzyl-1-thio- $\alpha$ / $\beta$ -D-glucopyranoside (**7**) under the agency of *N*-iodosuccinimide and trifluoromethanesulfonic acid (*cat.*) afforded  $\alpha$ -linked dimer **10** in 95% yield. Vorbrüggen-type condensation of **12**, obtained by deacetonation of **10** and subsequent acetylation, with bis-trimethylsilyl *N*<sup>6</sup>-benzoyl adenine gave adenosyl glucoside **13**. Protective group manipulations followed by phosphorylation furnished, after deprotection, homogeneous **2** in high overall yield. Copyright © 1996 Elsevier Science Ltd

Stimulation of an extracellular G-protein coupled receptor induces in many cell types intracellular Ca<sup>2+</sup> mobilization *via* the second messenger *D*-*myo*-inositol 1,4,5-triphosphate<sup>1</sup> (IP<sub>3</sub>, **1**). Growing evidence indicates that IP<sub>3</sub> may be an essential element in various cellular functions, *i.e.* smooth muscle contractility, secretion, neuronal excitability, the activation of inflammatory cells and cell proliferation. Recently, adenophostins A (**2**) and B (**3**), isolated from the fermentation broth of *Penicillium brevicompactum* SANK 11991 and SANK 12177, were discovered as potent IP<sub>3</sub> receptor agonists<sup>2</sup>, with a 100 times higher IP<sub>3</sub> receptor-binding affinity and Ca<sup>2+</sup>-mobilizing activity in comparison<sup>3</sup> with the natural ligand IP<sub>3</sub>.




1 IP<sub>3</sub>

2 R<sup>1</sup> = H, R<sup>2</sup> = P(O)(OH)<sub>2</sub>, R<sup>3</sup> = H (Adenophostin A)

3 R<sup>1</sup> = Ac, R<sup>2</sup> = P(O)(OH)<sub>2</sub>, R<sup>3</sup> = H (Adenophostin B)

4 R<sup>1</sup> = H, R<sup>2</sup> = H, R<sup>3</sup> = P(O)(OH)<sub>2</sub>



5

6

7

8


9

Recently, Hotoda *et al.*<sup>4</sup> reported for the first time an eight-step approach to the synthesis of adenophostin A (**2**) using 2-*O*-benzyl-3,4,6-tri-*O*-acetyl- $\alpha$ -D-glucopyranosyl bromide (**5**) and di-*N*<sup>6</sup>-benzoyl-2'-*O*-*p*-methoxybenzyl-5'-*O*-monomethoxytrityl adenosine (**6**) as the building units. Glycosylation of **6** with **5** under the influence of AgClO<sub>4</sub> followed by protective group manipulations of the resulting  $\alpha$ -linked dimer and subsequent phosphorylation gave, after deprotection, compound **2** in 22% overall yield.

With the objective to get an insight into the structure activity relationship of this new type of second messengers, we here report a versatile approach to the preparation of adenophostin A based on the properly protected units ethyl 1-thio- $\alpha$ / $\beta$ -D-glucopyranoside **7**, the ribofuranoside **8** and the adenine derivative **9**.


The route of synthesis is depicted in Scheme 1 and commences with the introduction of the requisite 1,2-*cis* linkage between the glucopyranosyl donor **7** and the ribofuranoside acceptor **8**. It was anticipated<sup>5</sup> that glycosylation of **8** with **7**, readily available by treatment of 1,3,4,6-tetra-*O*-acetyl-2-*O*-benzyl- $\alpha$ -D-glucopyranose with (ethylthio)trimethylsilane in the presence of trimethylsilyl trifluoromethanesulfonate (TMSOTf)<sup>6</sup>, would proceed with a high degree of  $\alpha$ -stereoselectivity. Indeed, idonium ion (NIS)-catalytic triflic acid (TfOH) mediated condensation of **7** with **8**, prepared from known<sup>7</sup> 1,2-*O*-isopropylidene- $\alpha$ -D-xylofuranose in three steps<sup>8</sup>, led to the exclusive formation of the  $\alpha$ -linked dimer **10**<sup>9</sup>. Unexpectedly, the purposive deacetonation of **10** in a mixture of acetic acid-water under reflux conditions was accompanied by cleavage of the interglycosidic linkage and partial removal of the *tert*-butyldiphenylsilyl (TBDPS) group. However, a high yielding and smooth transformation of **10** into **11**<sup>9</sup> was attained by unleashing the 1,2-*O*-isopropylidene function with HOAc-H<sub>2</sub>O containing ethylene glycol. Acetylation of the 1,2-diol function in **11** gave key intermediate **12**<sup>9</sup> in 75% yield over the three steps.

Scheme 1



**Reagents and conditions:** (i) NIS/*cat.* TfOH, (CH<sub>2</sub>Cl)<sub>2</sub>/Et<sub>2</sub>O (1:1, v/v), 5 min, 95% ( $\alpha:\beta = 1:0$ ); (ii) HOAc/H<sub>2</sub>O/(HOCH<sub>2</sub>)<sub>2</sub> (6:14:3, v/v/v), reflux, 30 min, 84%; (iii) Ac<sub>2</sub>O, pyr, 4 h, 94%; (iv) (Me<sub>3</sub>Si)<sub>2</sub>A<sup>Bz</sup>, TMSOTf, (CH<sub>2</sub>Cl)<sub>2</sub>, reflux, 16 h, 71%; (v) KO<sup>t</sup>-Bu/MeOH (1M)/dioxane (2:1, v/v), 1 min, 96%; (vi) a. TBAF/THF (1M)/dioxane (1:3, v/v), 40 °C, 2 h; b. DMTCl, pyr, 16 h, 65% (two steps); (vii) a. **16**, 1*H*-tetrazole, CH<sub>2</sub>Cl<sub>2</sub>, 15 min; b. *t*-BuOOH, 0 °C, 5 min; (viii) a. NaOH (4N)/dioxane/MeOH, 1/14/5, v/v/v, 16 h; b. HOAc/H<sub>2</sub>O, 8/2, v/v, 1 h, 86% (based on **15**).

Vorbrüggen condensation<sup>10</sup> of **12** with the bis-trimethylsilyl derivative of **9** led to the isolation of the fully protected adenosyl glucoside **13**. In order to introduce the requisite phosphate groups, compound **13** was now subjected to the following protective group manipulations. Deacetylation of **13** to yield **14** was effected by short treatment with KO $t$ -Bu in methanol. Removal of the TBDPS group in **14** with fluoride ions, and subsequent regioselective masking of the two primary hydroxyl functions with 4,4'-dimethoxytrityl (DMT) groups, led to the isolation of the triol-derivative **15** in 62% yield (based on **13**). Phosphorylation of **15** was readily accomplished using the recently by us developed<sup>11</sup> reagent *N,N*-diisopropyl-bis [2-(methylsulfonyl)ethyl] (MSE) phosphoramidite (**16**). Thus, 1*H*-tetrazole assisted phosphitylation of **15** with **16**, followed by *in situ* oxidation (*t*-BuOOH) of the intermediate phosphite triesters, gave the fully protected derivative **17**<sup>12</sup>. A one-pot sequential removal of the base labile benzoyl and 2-(methylsulfonyl)ethyl and the acid labile 4,4'-dimethoxytrityl groups from **17** gave, after purification by HW-40 gel filtration, the mono-benzyl protected derivative **18** in 86% yield (based on **15**). Finally, hydrogenation of **18** with Pd-black-H<sub>2</sub>O (1 atm. H<sub>2</sub>) gave, after gel filtration (HW-40), homogeneous **2**<sup>13</sup> (65% yield, Na<sup>+</sup>-salt), the spectroscopic data - <sup>1</sup>H as well as <sup>13</sup>C-NMR spectroscopy - of which were in full accord with those reported for naturally occurring<sup>2</sup> and synthetic<sup>4</sup> adenophostin A. In addition, the two-dimensional <sup>1</sup>H-<sup>31</sup>P correlated NMR-spectrum of **2** (see Fig. 1) firmly established the presence of two (3''-4'')-*trans* oriented phosphate groups in the glucopyranosyl moiety. The spatial arrangement of the latter two phosphates was also independently confirmed by comparison (see Fig. 1) of the <sup>1</sup>H-<sup>31</sup>P correlated spectrum of **2** with that of synthetically prepared<sup>14</sup> adenophostin A analogue **4** containing (2''-4'')-*cis* oriented phosphate groups.



**Figure 1.** <sup>1</sup>H-<sup>31</sup>P Correlated NMR spectra of compounds **2** (A) and **4** (B).

The successful assembly of adenophostin A (28% yield over the nine steps) is mainly due to the high yielding and stereoselective synthesis of dimer **10** and its smooth conversion into the functionalized dimer **12**. The synthesis of other biologically interesting analogues of adenophostin A starting from the now readily available dimers **10-12** will be reported in due course.

## References and Notes

1. (a) Berridge, M.J. *Ann. Rev. Biochem.* **1987**, *56*, 159; (b) Berridge, M.J. *Nature (London)*, **1993**, *361*, 315.

2. (a) Takahashi, M.; Kagasaki, T.; Hosoya, T.; Takahashi, S. *J. Antibiot.* **1993**, *46*, 1643; (b) Takahashi, S.; Kinoshita, T.; Takahashi, M. *ibid.* **1994**, *47*, 95; (c) Takahashi, M.; Tanzawa, K.; Takahashi, S. *J. Biol. Chem.* **1994**, *269*, 369.
3. Depending on the assay system the potency of adenophostin A may be only 10 times that of IP<sub>3</sub> (*FEBS Lett.* **1995**, *368*, 248).
4. Hotoda, H.; Takahashi, M.; Tanzawa, K.; Takahashi, S.; Kaneko, M. *Tetrahedron Lett.* **1995**, *36*, 5037.
5. (a) Veeneman, G.H.; Van Boom, J.H. *Tetrahedron Lett.* **1990**, *31*, 275; (b) Veeneman, G.H.; Van Leeuwen, S.H.; Van Boom, J.H. *Tetrahedron Lett.* **1990**, *31*, 1331.
6. Pozsgay, V.; Jennings, H.J. *Tetrahedron Lett.* **1987**, *28*, 1375.
7. Moravcova, J.; Capková, J.; Stanek, J. *Carbohydrate Res.* **1994**, *263*, 61.
8. 1,2-*O*-Isopropylidene- $\alpha$ -D-xylofuranose was regioselectively silylated with *tert*-butyldiphenylsilyl chloride. Oxidation of the resulting product with DMSO/Ac<sub>2</sub>O and reduction of the ulose derivative with NaBH<sub>4</sub> afforded crystalline (ethanol) **8** in 60% yield.
9. Relevant spectroscopic data (CDCl<sub>3</sub>): (**10**): <sup>1</sup>H-NMR:  $\delta$  5.87 (d, 1H, H-1, J<sub>1,2</sub> = 3.7 Hz), 5.32 (d, 1H, H-1', J<sub>1',2'</sub> = 3.7 Hz); <sup>13</sup>C-NMR:  $\delta$  104.2 (C-1), 94.3 (C-1', J<sub>C-1, H-1</sub> = 171.5 Hz); ESI-MS [M+H]<sup>+</sup> 807; (**11**): <sup>13</sup>C-NMR:  $\delta$  101.6 (C-1  $\beta$ ), 97.7 (C-1'), 96.6 (C-1  $\alpha$ ); ESI-MS [M+Na]<sup>+</sup> 789; (**12**): <sup>13</sup>C-NMR:  $\delta$  98.5 (C-1  $\alpha$ ), 97.1 (C-1'); ESI-MS [M+Na]<sup>+</sup> 873.
10. Vorbrüggen, H.; Krolkiewicz, K.; Bennua, B. *Chem. Ber.* **1981**, *14*, 1234.
11. Wijsman, E.R.; Van den Berg, O.; Kuyl-Yeheskiely, E.; Van der Marel, G.H.; Van Boom, J.H. *Recl. Trav. Chim. Pays-Bas*, **1994**, *113*, 337.
12. <sup>31</sup>P-NMR (CH<sub>2</sub>Cl<sub>2</sub>):  $\delta$  -2.01, -2.33, -2.63.
13. Relevant spectroscopic data of target compound **2**: <sup>1</sup>H-NMR (D<sub>2</sub>O):  $\delta$  8.28 (s, 1H, H-8), 8.10 (s, 1H, H-2), 6.24 (d, 1H, H-1', J<sub>1',2'</sub> = 6.7 Hz), 5.33 (d, 1H, H-1'', J<sub>1'',2''</sub> = 3.8 Hz), 5.26 (ddd, 1H, H-2', J<sub>2',3'</sub> = 2.7 Hz, <sup>3</sup>J<sub>HP</sub> = 9.8 Hz), 4.46 (m, 2H, H-4', H-3''), 4.00 (q, 1H, H-4'', J<sub>3'',4''</sub> = J<sub>4'',5''</sub> = 9.9 Hz, <sup>3</sup>J<sub>HP</sub> = 9.9 Hz); <sup>13</sup>C-NMR (D<sub>2</sub>O):  $\delta$  155.7, 149.0 (C-4, C-6), 152.2, 142.0 (C-2, C-8), 119.7 (C-5), 98.7 (C-1''), 88.2 (C-1'), 77.7 (C-3'', <sup>2</sup>J<sub>CP</sub> = 8.2 Hz), 75.7 (C-2', <sup>2</sup>J<sub>CP</sub> = 4.3 Hz), 72.6 (C-4'', <sup>2</sup>J<sub>CP</sub> = 3.3 Hz); <sup>31</sup>P-NMR (D<sub>2</sub>O):  $\delta$  2.44 (C-4'' P), 1.91 (C-3'' P), 0.79 (C-2' P); ESI-MS [M-H]<sup>-</sup> 668.
14. The synthesis of **4** was accomplished by subjecting **10** to the following sequence of reactions: a. H<sub>2</sub>, Pd(C); b. pivaloyl chloride (76% over the two steps); c. HOAc-H<sub>2</sub>O-(HOCH<sub>2</sub>)<sub>2</sub>; d. Ac<sub>2</sub>O; e. (Me<sub>3</sub>Si)<sub>2</sub>ABz, TMSOTf; f. KO<sup>t</sup>-Bu, methanol; g. TBAF; h. DMT-Cl; i. **16**, 1*H*-tetrazole; j. *t*-BuOOH; k. NaOH; l. HOAc-H<sub>2</sub>O. The conditions and yields of the individual steps c-l did not deviate substantially from the steps ii-viii mentioned in Scheme 1. Interestingly, step f led to a near quantitative migration of the pivaloyl group to the 3''-position in the glucosyl moiety. Relevant spectroscopic data for **4**: <sup>1</sup>H-NMR (D<sub>2</sub>O):  $\delta$  8.31 (s, 1H, H-8), 8.21 (s, 1H, H-2), 6.28 (d, 1H, H-1', J<sub>1',2'</sub> = 6.0 Hz), 5.39 (d, 1H, H-1'', J<sub>1'',2''</sub> = 3.3 Hz), 5.23 (ddd, 1H, H-2', J<sub>2',3'</sub> = 3.7 Hz, <sup>3</sup>J<sub>HP</sub> = 9.0 Hz), 4.22 (m, 1H, H-2''), 4.02 (t, 1H, H-3'', J<sub>2'',3''</sub> = J<sub>3'',4''</sub> = 9.8 Hz), 3.94 (q, 1H, H-4'', J<sub>4'',5''</sub> = 9.7 Hz, <sup>3</sup>J<sub>HP</sub> = 9.2 Hz); <sup>13</sup>C-NMR (D<sub>2</sub>O):  $\delta$  149.6, 142.2 (C-4, C-6), 120.2 (C-5), 98.4 (C-1'), 88.8 (C-1''), 75.2 (C-3''), 75.1 (C-2', <sup>2</sup>J<sub>CP</sub> = 4.8 Hz), 73.4 (C-4'', <sup>2</sup>J<sub>CP</sub> = 4.7 Hz), 72.6 (C-2'', <sup>2</sup>J<sub>CP</sub> = 5.6 Hz); <sup>31</sup>P-NMR (D<sub>2</sub>O):  $\delta$  3.64 (C-4'' P), 1.61 (C-2' P), 1.20 (C-2'' P).

(Received in UK 11 March 1996; accepted 3 April 1996)